Frontier Clinical Research, LLC

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Migraine3 trials
• Irritable bowel syndrome2 trials
• Lyme disease2 trials
• Type 2 diabetes2 trials
• Obesity1 trial

Phase

• Phase 37 trials
• Phase 22 trials

Status

• Completed4 trials
• Recruiting4 trials
• Enrolling by invitation1 trial

Lead sponsor

• TriGemX Bio, Inc.3 trials
• Ardelyx2 trials
• Eli Lilly and Company2 trials
• Pfizer2 trials

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

  NCT07500506· Phase 3· Pfizer· Source

• Recruiting

  A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  NCT06897475· Phase 2· Eli Lilly and Company· Source

  Contact: Tiffany Pluto (principal investigator)

• Enrolling by invitation

  Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

  NCT05905926· Phase 3· Ardelyx· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine2 recruiting
• Irritable bowel syndrome1 recruiting
• Lyme disease1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

  NCT06848075· Phase 2· TriGemX Bio, Inc.· Source

• Completed

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

  NCT05643534· Phase 3· Ardelyx· Source

• Completed

  An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Phase 3· Pfizer· Source